Hilar(ious) Or Not?

My hilar lymph nodes have become one of the main areas of focus in my cancer surveillance after thoracic surgery to remove a metastatic PSCC nodule from my left lower lung. Hilar nodes sit deep near the center of the lungs where the bronchi and major blood vessels enter and exit. In my most recent CT report, the radiologist described the left hilar nodes as “mildly enlarged” and “indeterminate,” meaning they cannot yet say with confidence whether the changes are simply related to post-surgical inflammation and healing or whether they could represent early nodal metastatic disease. Right now, these nodes represent one of those difficult gray areas in cancer follow-up where careful monitoring, repeat imaging, and informed questions matter more than rushing to conclusions.

One reassuring detail is that these hilar nodes did not show FDG uptake on my recent PET scan. FDG stands for fluorodeoxyglucose, a radioactive glucose-like tracer used during PET imaging. After it is injected into the bloodstream, the body treats it similarly to sugar. Cells that are more metabolically active—such as cancer cells, inflamed tissue, healing tissue, the brain, or even muscles—absorb more FDG than quieter tissues. Once FDG enters a cell, it becomes partially trapped there long enough for the PET scanner to detect areas of increased activity. The radioactive component of FDG, fluorine-18, has a physical half-life of about 110 minutes, meaning the signal gradually fades over several hours as the tracer decays and is cleared from the body through the kidneys and urine.

The absence of FDG uptake in my hilar nodes lowers concern, but it does not completely eliminate uncertainty. Enlarged hilar nodes after thoracic surgery can sometimes be reactive, meaning they are responding to inflammation, healing, or immune activity rather than active cancer. At the same time, the radiologist noted a slight increase in size, which is why these nodes remain an important area to watch closely on future imaging. For now, the lungs remain the new focal area of my surveillance—not a reason for panic, but a reminder of how much cancer follow-up often lives in the space between reassurance and uncertainty.